Epcoritamab plus R-CHOP reduced the risk of progression or death by 51% vs R-CHOP alone in newly diagnosed DLBCL.
Opinion|Videos|November 1, 2024
Clinical Impact of ALK Inhibitor Data: Efficacy, Brain Metastases, and CNS Management Strategies
Panelists discuss how recent data influence treatment choices for ALK-positive NSCLC patients, highlighting specific patient factors that guide decisions and potential concerns regarding the use of lorlatinib as first-line therapy.
Advertisement
- Dr Gadgeel: How do these data impact your treatment choice for your patients?
- What specific patient factors would influence your decision between treatment options? What concerns might prevent you from choosing lorlatinib as a first-line treatment?
Advertisement
Related to this article
The 19-year veteran of CU Anschutz will be the fourth director in the 41-year history of Colorado’s only NCI-designated comprehensive cancer center.
The estimated 3-year OS rate with botensilimab plus balstilimab was 48% in heavily pretreated recurrent ovarian cancer in the phase 1b C-800-01 trial.
PRV111 produced pathologic complete responses in 21 of 22 patients with noninvasive oral cancer or high-grade dysplasia.
A patient treated at the highest dose level of lira-cel to date had stable disease 90 days after infusion in a phase 1 trial in recurrent ovarian cancer.
A randomized phase 2 trial of berzosertib plus carboplatin in pretreated mCRPC stopped for futility amid fewer responses and more high-grade toxicity than the control arm.
The top 5 OncLive TV videos of the week cover insights in MDS, multiple myeloma, pancreatic cancer, colorectal cancer, and uveal melanoma.
The combination nearly doubled the confirmed response rate in the randomized phase 2 portion of HexAgon-HN, with the greatest benefit in HPV-positive disease.
Advertisement
Advertisement
Trending on OncLive
1
Epcoritamab Plus R-CHOP Meets PFS End Point in Newly Diagnosed DLBCL
2
‘Our Impact Will Be Broad and Transformative’: Wells Messersmith, MD, Takes the Reins at CU Anschutz Cancer Center
3
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
4
Berzosertib Plus Carboplatin Fails to Improve Responses in Pretreated mCRPC
5